In December 2010, Targovax AS received a grant from Innovation Norway, “Etablererstipend”, of NOK 800 000, to further develop the company’s profile, strategy and business plan. The grant has supported the company in establishing a plan for a clinical phase II study with its lead candidate, TG01. The grant was matched with an equal sum from private investors, including The Radium Hospital Research Foundation.